We also show that the isogenic iPSC-based platform can be used to test therapeutic agents to treat HHI in infants homozygous for LoF KATP channels and screen for drugs that can improve glucose-responsive insulin secretion in adult heterozygous carriers. The gene discussed is INS; the disease is familial hyperinsulinism.